Full-Time

Field Medical Outcomes

Director, Non-MD

Posted on 10/1/2025

Deadline 10/15/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$169.7k - $282.9k/yr

+ Bonus

No H1B Sponsorship

Vermont, USA + 9 more

More locations: Jackson Township, NJ, USA | Waterbury, CT, USA | Concord, NH, USA | Rhode Island, USA | Kentucky, USA | New York, NY, USA | Massachusetts, USA | Ohio, USA | Indiana, USA

Remote

Candidates must be based in one of the listed states.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree in health science required
  • Relevant experience required: 8+ years with bachelor’s degree; 7+ years with master’s degree; 5+ years with terminal doctorate degree (PharmD, PhD)
  • Experience in Clinical, formulary, and/or other management experience
  • Experience in Managed Care, pharmaceutical industry, and/or Quality Improvement
  • Experience in Data Analytics and/or HEOR activities, with demonstrated strong methodological skills (study design, data analysis, and interpretation) in health services research
  • Significant experience in interacting with payers and other organized customers is required
  • Excellent oral and written communication skills required
  • Excellent and demonstrated interpersonal skills: ability to understand and respond to multiple external and internal customers’ demands, manage and handle conflict constructively required
  • Strong analytic skills including creativity and effectiveness in proactively identifying and addressing challenges
  • Strong comprehension and communication skills, including ability to communicate large amounts of scientific information in a manner that is clear and concise
  • Well-organized with the ability to be flexible, prioritize multiple demands, and employ strong situational leadership skills
  • Ability to travel, including overnight travel for internal and external meetings (customer, industry, and professional society meetings)
  • Ability to operate a Pfizer company car with a valid US Driver’s License and regularly fly on airplanes; must be within a 2-hour drive of a major airport; flexibility to potentially travel 40 – 50% of time
Responsibilities
  • Ensure compliance with all internal/external SOPs/Rules/Regulations
  • Provide objective and scientifically sound medical information regarding Pfizer’s medicines and the disease states they treat through use of pharmacoeconomic models, outcomes tools, educational programs, Health Outcomes Projects and Evaluations (HOPEs), non-interventional studies, and collaborations
  • Appropriately prioritize the needs of the customer and of Pfizer to develop and implement objective and scientifically sound Real-World Evidence-based outcomes tools (such as HOPEs and educational programs) which identify the greatest opportunities for improving patient care, closing quality gaps, and addressing population health management
  • Serve as the Field Medical Outcomes lead for assigned customers, developing and executing a medical account plan while representing Medical Affairs, sharing insights from the customer, and identifying opportunities for collaboration to improve patient care
  • Understand the principles of study design, methodology, data analysis, and interpretation and communicate these concepts with customers
  • Appropriately engage with key stakeholders within the market, such as Quality Improvement Organizations, Advocacy Groups, Coalitions, and other medical/healthcare associations, to understand their population health priorities and identify opportunities that align with the strategic medical objectives of Pfizer
  • Provide Medical support and guidance for HIT initiatives including initial assessment, triaging opportunities for review, assessing organizational capabilities and feasibility, and providing clinical relevance to proposed HIT methodologies
  • Analyze workflows in the context of clinical healthcare information systems to facilitate care processes to reduce care gaps, improve care efficiencies, and maximize quality and population health
  • Facilitate development of clinical content that embodies the clinical perspective while effectively using information technology to develop strategy and build innovative tools and resources
  • Provide expertise on e-data collection and planning for Field Medical colleagues
  • Work cross-functionally within Pfizer guidance to identify, design, and deploy HIT solutions aligned with Pfizer Medical goals for Field Medical use
  • Support development of HIT/clinical informatics specific resources for new product and new indication launches
  • Maintain, continually develop, and utilize Clinical Informatics capabilities to enable effective collaborations with external customers
  • Serve as members of internal teams to further the impact of Field Medical Outcomes by creating tools, resources, and educational materials for use both internally and externally
  • Represent Pfizer Medical Affairs leadership with clinical/professional associations and/or societies, consistently demonstrating medical professionalism in all interactions
  • Enhance customer recognition of Pfizer Medical through collaborative projects, publications and healthcare awards
  • Providing approved medical content on Pfizer’s products in the designated therapeutic area, with a primary focus on organized customers, including but not limited to National Payers, Regional Payers, and Specialty Pharmacy Providers (SPPs)
  • Demonstrate Pfizer Scientific Leadership by keeping abreast of medical and scientific developments in the designated therapeutic area by continuously reviewing literature in the field, evolving competitive landscape, networking with experts and attending assigned conferences
  • Respond to unsolicited requests from customers regarding scientific interpretation of clinical information and pharmacoeconomic impact of product selection to further advance formulary decision-making or patient outcomes through appropriate pharmaceutical care
  • Compliantly collaborate with internal Pfizer colleagues (including Key Account Managers, Account Directors, PHI, Field Medical, Headquarters Medical, CI, AME, and HEOR) to understand the outcomes of interest and data analysis needs of assigned customers
  • Maintain significant market and customer knowledge in an increasingly complex and dynamic marketplace
  • Manage a significant volume of projects developed in a field-based environment, while exhibiting the ability to prioritize, successfully implement, and demonstrate excellent judgment skills and work in a continuous improvement environment
  • Maintain an up-to-date status for internal training requirements
  • Conduct all activities in accordance with all relevant policies, procedures and compliance guidance
  • Educating HCOs based on patient care gaps and aligned to medical strategy with the goal of enhancing understanding of disease state and guideline-based care
  • Achieve leadership-defined expectations regarding the number of medical stakeholders engaged
  • Understand the priorities of PFE Medical Affairs in order to contribute to medical content strategy development and aligned field medical tactics
  • Provides strong territory/customer leadership
  • Serve on Medical, TA or cross-functional committees as appropriate
  • Mentorship and Onboarding partner
  • Maintain professional licensure and continually learn and grow in profession
Desired Qualifications
  • Previous experience in field-based medical/outcomes role
  • Experience analyzing health care data (claims, electronic health records, other health care data)
  • Expertise in Clinical Informatics or Health Information Technology (HIT), including working with claims data sets or Electronic Health Record (EHR) systems
  • Residency or Fellowship experience
  • Microsoft Access, statistics software, and/or data programming experience
  • Experience in the clinical, functional, and technical application of health information technology used in the U.S.
  • Experience with optimization/customization of EHR platforms, including developing EHR clinical solutions
  • Leadership in innovative project start-up and management
  • Understanding of the complex business environment within the US healthcare system as well as emerging healthcare trends

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer medicines grew 22% operationally in Q1 2026, led by Padcev up 39% and Lorbrena up 32%.
  • VYNDAMAX patent extended to 2031 secures 75% US prescription share in cardiology.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma use against J&J and BMS competitors.

What critics are saying

  • Eliquis patent expiry in 2026 triggers generic entry, eroding $17B peak cardiology sales.
  • Ibrance loses exclusivity in 2027, unleashing generics that destroy $5B breast cancer revenue.
  • Rigel deal forfeits Pfizer's Veppanu royalties, ceding 50-70% of breast cancer peak sales.

What makes Pfizer unique

  • Pfizer pioneered VEPPANU, FDA-approved first PROTAC therapy for ESR1-mutated breast cancer in May 2026.
  • Seagen acquisition doubled Pfizer's ADC trials across bladder, breast, lung, and colorectal cancers.
  • Flatiron Health collaboration since 2014 integrates real-world data for NSCLC and CRC development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE